Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NN9924 in Healthy Male Subjects

NCT01272973 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of the experimental drug NN9924 in healthy adult men to see how it is tolerated and processed by the body.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 96 people

Who can join Ages 18–60 · male only

Timeline Started 2011-01 · est. completion 2011-07

Where 1 site · Germany

What this study is testing ClinicalTrials.gov NCT01272973 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of the trial is to investigate safety, tolerability, pharmacokinetics (the rate at which the body eliminates the trial drug) and pharmacodynamics (the effect of the investigated drug on the body) of NN9924 in healthy male subjects

Treatments tested

semaglutide Drug

Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
placebo Drug

Placebo (oral) administered once daily for 10 weeks.
semaglutide also known as NN9924 Drug

Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.

Main thing measured	Frequency of adverse events (AEs)
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2, Healthy
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT01272973 ↗